Compare Invesco NASDAQ 100 ETF (QQQM) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Summit Therapeutics Inc — how do they compare? Invesco NASDAQ 100 ETF trades at $290.29, while Summit Therapeutics Inc trades at $14.68 (market cap $11.34B). The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| QQQM | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $307.23 | $29.32 |
52-Week Low | $228.02 | $13.05 |
Market Cap | — | $11.34B |
Enterprise Value | — | $10.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $286.58 with minimal daily movement (+0.09%) amid bearish technical signals. The ETF faces headwinds from stretched tech valuations and rising AI competition, though recent Nasdaq-100 additions like SpaceX provide diversification. Technical indicators show oversold conditions with RSI at 22.39, while moving averages signal continued downward pressure.
The outlook remains cautious due to valuation concerns and sector rotation risks. However, the lower 0.15% expense ratio versus QQQ offers cost efficiency for long-term growth exposure. Key risks include AI market saturation and tech sector volatility, balanced by the fund's concentrated exposure to leading U.S. innovation companies.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
